PN: B111206

COMPONENTS

1x Ab-conjugated beads (S4P8 - TGFβ1 Ab-bead).  PN: B111206A. One vial containing 5 mL of anti-TGFβ1 conjugated to AimPlex Bead S4P8.

2x Biotin-detection Ab(TGFβ1 Biotin-dAb). PN: B111206B. One vial containing 1.5 mL of biotinylated anti- TGFβ1.

2x TGFβ dAb Diluent. PN: 07TDX21. One vial containing 1.5 mL of biotin detection antibody diluent.

Lyophilized Standard - TGFβ1. PN: UTGFB1AG. One vial containing lyophilized recombinant TGFβ1.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human, mouse, rat, porcine, canine and Non-Human Primate (NHP) TGFβ1. To be used in conjunction with the AimPlex Basic Kit for Premixed Panels (PN: U100005) and the TGFβ Diluent Kit (PN: P900110, universal for all sample types). Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

NOTE: Samples should be pretreated with HCl then neutralized to activate latent TGFβ1 to the immunoreactive form for accurate measurement. Do not pretreat the TGFβ1 Standard. Add 20 µL of 1N HCl to 100 µL of sample. Incubate for 10 minutes at room temperature after mixing. Neutralize with an addition of 20 µL of 1.2N NaOH/0.5M HEPES. The activated samples may need to be diluted with Sample Dilution Buffer (PN: P830100) for the assay. The appropriate dilution factor should be determined by the investigator according to the sample type and experimental conditions. Because of the sample pretreatment, the TGFβ1 assay cannot be multiplexed with any other AimPlex assays. 

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 50 pg/mL

Quantitation range:

LLOQ: < 100 pg/mL

ULOQ: > 20,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Sample volume: 15 µL/test

Description:

Vascular Endothelial Growth Factor A (VEGF-A) is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. As its name implies, VEGF-A activity has been studied mostly on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g., stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). In vitro, VEGF-A has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF-A functions as a vasodilator and increases microvascular permeability. It was originally referred to as vascular permeability factor. Diseases associated with VEGFA include microvascular complications of diabetes 1 and POEMS syndrome.

References:

1.      Ghadami M, Makita Y, Yoshida K, Nishimura G, Fukushima Y, Wakui K, Ikegawa S, Yamada K, Kondo S, Niikawa N, Tomita Ha (January 2000). "Genetic mapping of the Camurati-Engelmann disease locus to chromosome 19q13.1-q13.3". Am. J. Hum. Genet. 66 (1): 143–7. doi:10.1086/302728. PMC 1288319. PMID 10631145.

2.      Vaughn SP, Broussard S, Hall CR, Scott A, Blanton SH, Milunsky JM, Hecht JT (May 2000). "Confirmation of the mapping of the Camurati-Englemann locus to 19q13. 2 and refinement to a 3.2-cM region". Genomics 66 (1): 119–21. doi:10.1006/geno.2000.6192. PMID 10843814.

3.      Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB (1983). "Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization". J. Biol. Chem. 258 (11): 7155–60. PMID 6602130.Letterio JJ, Roberts AB (1998). "Regulation of immune responses by TGF-beta". Annu. Rev. Immunol. 16: 137–61. doi:10.1146/annurev.immunol.16.1.137. PMID 9597127.

4.      Letterio JJ, Roberts AB (1998). "Regulation of immune responses by TGF-beta". Annu. Rev. Immunol. 16: 137–61. doi:10.1146/annurev.immunol.16.1.137. PMID 9597127.